**吕蓓妮, MD, PhD**

**助理教授，研究员**

北京大学全球健康发展研究院

地址：北京市海淀区颐和园路 5 号24号楼 100871

邮箱：blyu@pku.edu.cn

**工作经历**

2022/09 至今 北京大学全球健康发展研究院 助理教授、研究员

2021/06 - 2022/06 美国约翰霍普金斯大学布隆伯格公共卫生学院流行病系 助理研究员

**教育经历**

2017/09 – 2021/05 美国威斯康星大学麦迪逊分校 流行病学博士学位

导师：Brad Astor教授

2008/09 – 2016/07 北京大学 临床医学博士学位（八年制）

导师：赵明辉、陈育青教授

**课题项目**

* 2025.01-2027.12 国家自然科学基金青年项目

基于社会生态学理论的老年人多重用药临床决策机制分析和实证研究（72404006），**主持**（30万）

* 2024.10-2027.9 北京市自然科学基金-海淀原始创新联合基金前沿项目

基于真实世界数据的机器人辅助髋膝关节置换术临床效能和卫生经济学评价 （L242168），**主持**（30万）

* 2024.1-2024.12 北京大学医学机器人卫生技术评估队列调查平行研究

Clinical efficacy and health economics evaluation of robot-assisted hip and knee replacement based on real-world data，**主持** （10万）

* 2025.1-2026.12 四川省重点研发项目（省院省校科技合作）

面向代谢综合症发展风险评估的融合语义理解的DIA质谱智能分析技术，**参与**

* 2018.1-2022.12 美国国立卫生研究院糖尿病、消化和肾脏疾病研究所基金

Medication Use and Adverse Events in CKD，**参与**

**论文发表（\*通讯作者）**

1. Xiao N, Li R, Li S, Yu Y, Yang F, Yang J, Liu GG, **Lyu B**\*. Associations of serial negative income shock and all-cause mortality: a longitudinal study in China. ***BMJ Public Health.*** 2024. 2 (2).
2. Li S, Pan S, Jiang S, Shin JI, Liu GG, **Lyu B**\*. Prescription medication use among patients with type 2 diabetes in the United States: 1999-2020. ***Diabetes Obes Metab***. 2024. doi: 10.1111/dom.15619.
3. Pan S, Li S, Jiang S, Shin JI, Liu GG, Wu H, **Lyu B\*.** Trends in Number and Appropriateness of Prescription Medication Utilization among Community-Dwelling Older Adults in the US: 2011-2020. ***J Gerontol A Biol Sci Med Sci***. 2024. doi: 10.1093/gerona/glae108.
4. Wu Z, Yu J, **Lyu B**, Lin H, Li S, Liu GG. Alcohol Consumption Patterns for Excessive Drinkers in a Multi-Ethnic Society Short Running Title: Drinking Patterns and Health Education. ***Risk Manag Healthc Policy.*** 2024. Jun 12:17:1577-1586
5. Xu Y, Boyle TA**, Lyu B**, Ballew SH, Selvin E, Chang AR, Inker LA, Grams ME, Shin JI. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. ***J Gen Intern Med***. 2024. doi: 10.1007/s11606-023-08589-3.
6. **Lyu B\*,** Inker LA, Shin JI. In Reply to Comparison of Measured and Estimated GFR for Rivaroxaban Dosing in Hospitalized Older Adults. ***Am J Kidney Dis.*** 2024 Jan;83(1):118.
7. **Lyu B\*,** Xu Y, Inker LA, Chang AR, Nolin TD, Coresh J, Grams ME, Shin JI. Discordance in GFR Estimating Equations and Dosing Guidance by Body Mass Index and Age. ***Am J Kidney Dis.*** 2023 Oct;82(4):505-507.
8. Sun J, You R, **Lyu B,** Li X, Gao Y, Wen Y, Qu C, Wang Y. HLA-DR Helps to Differentiate Erythrodermic Cutaneous T-cell Lymphoma from Erythrodermic Inflammatory Dermatoses in Flow Cytometry***. Acta Derm Venereol***. 2023 Aug 1;103:adv5668.
9. The association between socioeconomic status and use of potentially inappropriate medications in older adults. Hwang J, **Lyu B**, Ballew S, Coresh J, Grams ME, Couper D, Lutsey P, Shin JI.

***J Am Geriatr Soc***. 2023. doi: 10.1111/jgs.18165.

1. **Lyu B,** Sang Y, Selvin E, Chang AR, Alexander CG, Cohen CM, Coresh J, Shaleve V, Chodick G, Karasik A, Carrero JJ, Fu EL, Xu Y, Grams ME, Shin JI. Pharmacologic Treatment of Type 2 Diabetes in the United States, Sweden, and Israel: A Comparison across three Health Systems. ***Diabetes Care***. 2022; 45(12):2926-2934.

Diabetes time report: <https://diabetestimes.co.uk/global-pharmacologic-treatments-of-type-2-diabetes-outlined-in-new-study/>

Elsevier Practice Update: <https://www.practiceupdate.com/content/pharmacologic-treatment-of-type-2-diabetes-in-the-us-sweden-and-israel/144124>

1. **Lyu B,** Singh T, Astor BC. Epidemiology and outcomes for chronic kidney disease. ***Nephrology Self-Assessment Program***. 2022; 21 (2).
2. **Lyu B**, Hwang YJ, Selvin E, Jameson BC, Chang AR, Grams ME, Shin JI**.** Antidiabetic agents and the risk of hypoglycemia: a real-world study. ***Journal of General Internal Medicine***. 2023;38(1):107-114.
3. **Lyu B**, Chang AR, Inker LA, Selvin E, Grams ME, Shin JI**.** Socioeconomic Status and obesogenic medication use in the United States. ***the Lancet Regional Health-Americas****.* 11 (2022): 100249*.*

*The Lancet Regional Health-Americas Editorial Commentaries:* [*Obesogenic and leptogenic medication utilization in people with obesity: Is there a prescription for improvement?*](https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00076-X/fulltext)

Healio Primary Care news: <https://www.healio.com/news/primary-care/20220419/adults-with-lower-socioeconomic-status-more-likely-to-use-obesogenic-medications>

1. **Lyu B**, Grams ME, Inker LA, Chang AR, Selvin E, Shin JI**.** Weight changes following antidiabetic mediation use: real-world evidence from health system data. ***Obesity Science & Practice***.2022. Feb 17;8(5):657-669.
2. **Lyu B**, Grams ME, Chang AR, Inker LA, Coresh J, Shin JI. SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP4 Inhibitors and risk of hospitalization. ***American Journal of cardiology***. 2022 Feb 15;165:124-130.

Faculty opinions recommendation: [Faculty Opinions: Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.](https://facultyopinions.com/article/741410199)

1. **Lyu B,** Chan MR, Yevzlin AS, Gardezi A, Astor BC. Arteriovenous access and risk of mortality and hospitalization among elderly hemodialysis patients- a target trial emulation approach. ***American Journal of Kidney Diseases***. 2022 Jan;79(1):69-78.

Healio Nephrology news: <https://www.healio.com/news/nephrology/20210630/arteriovenous-access-types-demonstrate-similar-risk-profiles>

USRDS Publication Spotlight: <https://www.usrds.org/publications/>

1. Panthofer AM, **Lyu B**, Astor BC, Singh T, Aziz F, Mandelbrot DA, Parajuli S, Mohamed M, Djamali A, Garg N. Post-Kidney Transplant Serum Magnesium Exhibits a U-Shaped Association with Subsequent Mortality: An Observational Cohort Study.***Transplant International.*** 2021 Oct;34(10):1853-1861.
2. Hwang YJ, **Lyu B**, Chang AR, Inker LA, Grams ME, Shin JI. Sodium-glucose cotransporter-2 inhibitors and the risk of abnormal serum potassium level: a population-based cohort study. ***Clinical Journal of American Society of Nephrology.*** 2021 Jul;16(7):1094-1096.
3. **Lyu B**, Mandelbrot DA, Djamali A, Astor BC. Graft Function Variability and Slope and Kidney Transplantation Outcomes. ***Kidney International Reports.*** 2021.6(6):1642-1652.
4. **Lyu B**, Chan MR, Yevzlin AS, Astor BC. Catheter dependence after arteriovenous fistula or graft placement among elderly patients on hemodialysis. ***American Journal of Kidney Diseases***. Am J Kidney Dis. 2021 Sep;78(3):399-408.
5. **Lyu B**, Hansen KE, Jorgenson MR, Astor BC. Proton pump inhibitor and H2 receptor antagonist use and change in bone mineral density among kidney transplant recipients. ***Am J Nephrol***. 2020;51(6):433-441.
6. **Lyu B**, Jorgenson MR, Hansen KE, Djamali A, Astor BC. Proton pump inhibitors, but not H2 receptor antagonists, are associated with incident fractures among kidney transplant recipients. Transplantation***. Transplantation***. 2020;104(12):2609-2615.
7. **Lyu B**, Hagen EW, Ravelo LA, Peppard PE. Blood pressure dipping and sleep quality in the Wisconsin Sleep Cohort.  ***J Hypertens***. 2020; 38(3):448-455.

*J Hypertens Editorial Commentaries:* [Time to rethink the management of underlying sleep disturbances in nondippers?](https://journals.lww.com/jhypertension/Fulltext/2020/03000/Time_to_rethink_the_management_of_underlying_sleep.6.aspx)

1. Jorgenson MR, Descourouez JL, **Lyu B,** Astor BC, Saddler CM, Mandelbrot DA, Parajuli S. Management of BK Viremia is Associated with a Lower Risk of Subsequent Cytomegalovirus Infection in Kidney Transplant Recipients. ***Clin Transplant***. 2020;34(3):e13798.
2. Tiwari R, **Lyu B**, Alagusundaramoorthy S, Astor BC, Mandelbrot DA, Parajuli S. Association of diagnosed obstructive sleep apnea with kidney transplant outcomes. ***Clin Transplant****.* 2019; 33(12).
3. Jorgenson MR, Descourouez JL, **Lyu B**, Astor BC, Garg N, Smith JA, Mandelbrot DA. The Risk of Cytomegalovirus Infection after Treatment of Acute Rejection in Renal Transplant Recipients. ***Clin Transplant.*** 2019; 33(8):e13636.
4. Jorgenson MR, Descourouez JL, Cardinale B, **Lyu B**, Astor BC, Garg N, Saddler CM, Smith JA, Mandelbrot DA. Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes. ***Transpl Infect Dis***. 2019 Jun; 21(3):e13080.
5. **Lyu B**, Banerjee T, Scialla JJ, Shafi T, Yevzlin AS, Powe NR, Parekh RS, Astor BC. Vascular Calcification Markers and Hemodialysis Vascular Access Complications. ***Am J Nephrol***. 2018; 48(5):330-338.
6. Cai W, Hite ZL, **Lyu B**, Wu Z, Lin Z, Gregorich ZR, Messer AE, McIlwain SJ, Marston SB, Kohmoto T, Ge Y. Temperature-sensitive sarcomeric protein post-translational modifications revealed by top-down proteomics. ***J Mol Cell Cardiol***. 2018; 122:11-22.

**荣誉和奖励**

* 国家优秀自费留学生奖学金， 2022年
* 威斯康星大学Donn D’Alessio 优秀毕业生，2021年
* 威斯康星大学麦迪逊分校Holtz Center科技研究Mini奖学金， 2020年
* 美国肾脏病学会肾脏之星奖（ASN Kidney STARS award），2020年
* 美国心脏协会心血管疾病学生研究奖学金(Student Scholarships in Cardiovascular research)，2020年

研究课题（research proposal）：肾移植受者的移植物功能与心血管事件的风险

* 威斯康星大学麦迪逊校区学生研究旅行奖（Student Research Travel Award），2019年

**学术报告**

国际药物经济学与结果研究协会（ISPOR）欧洲年会，哥本哈根，2023年11月

* Trends in prescription drug use among adults with diabetes in the United States From 1999-2018
* Description of polypharmacy and PIM use trends in the elderly from the perspective of deprescribing

美国诊断与介入肾脏病学会(ASDIN)第19届年会，线上，2023年2月

* Exploring the role of community characteristics and race on vascular access management

美国心脏病协会EPI | Lifestyle and Cardiometabolic Health Scientific Sessions，芝加哥，2022年3月

* Socioeconomic status and use of obesogenic and anti-obesity medications in the United States-a population-based study

美国肾脏病学会年会，线上，2021年11月

* Weight changes following antidiabetic mediation use: real-world evidence from health system data

美国糖尿病协会第81届科学年会，线上，2021年6月

* SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization

威斯康星大学麦迪逊校区肾脏病学系grand rounds，威斯康星州麦迪逊，2020年11月

* Emulating target randomized controlled trials using electronic medical records

美国肾脏病学会年会，线上，2020年10月

* Catheter dependency after vascular access placement among elderly patients on hemodialysis: an intention-to-treat analysis.
* Vascular access type and risk of mortality and hospitalization among elderly hemodialysis patients: a target trial emulation approach.
* Short-term variability in graft function is associated with long-term mortality but not allograft survival in kidney transplant recipients.

威斯康星大学麦迪逊校区肾脏病学系grand rounds，威斯康星州麦迪逊，2020年1月

* Proton pump inhibitors and the kidney

美国肾脏病学会年会， 华盛顿特区，2019年 11月

* Proton pump inhibitors use and risk of major fracture in kidney transplant recipients

美国流行病学研究学会第52届年会，明尼苏达州明尼阿波利斯，2019年7月

* Proton pump inhibitors and H2 receptor antagonist use and change in bone mineral density among kidney transplant recipients